Contra-indicated in patients with active pathological bleeding.
- TRADE NAME: Bevyxxa (Portola)
- INDICATIONS: Prophylaxis of venous thromboembolism in adult patients hospitalized for an acute medical illness who are at risk for thromboembolic complications
- CLASS: Direct factor Xa inhibitor
- HALF-LIFE: 19–27 hours
- FDA APPROVAL DATE: 06/23/2017
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Amiodarone, Anticoagulants, antiplatelet drugs and thrombolytics, Azithromycin, Clarithromycin, Ketoconazole, Verapamil - PREGNANCY: Likely to increase the risk of hemorrhage during pregnancy and delivery
- See adverse reactions attributed to class:
SPINAL/EPIDURAL HEMATOMA
See full prescribing information for complete boxed warning.
Please login to view the rest of this drug profile.
Page last updated 07/31/2023
